+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

D

Actively Recruiting

Healthy Volunteer

Researchers are investigating swallowing disorders in intensive care unit patients who have tracheostomies and face difficulties weaning from mechanical ventilation. These disorders can lead to serious problems like respiratory complications and poor nutrition. The study aims to develop and test a new ultrasound-based diagnostic model to improve detection of swallowing difficulties, offering a less invasive alternative to current methods such as videofluoroscopy or Fiberoptic Endoscopic Evaluation of Swallowing FEES. This observational study will enroll 119 difficult-to-wean tracheostomised patients over a nineteen-month period at multiple hospitals. Each participant will undergo FEES and ultrasound evaluations within a two-hour timeframe. Ultrasound will assess movements and structures involved in swallowing, including the tongue, hyoid bone, and suprahyoid muscles. The ultrasound operator will be blinded to other patient information. The study will use logistic regression to create an ultrasound diagnostic score, which will be evaluated for its accuracy and reliability. Participants will have demographic and medical data collected alongside the swallowing assessments. Ultrasound measurements will be performed in a semi-recumbent position, focusing on muscle thickness, movement, and contraction. Reliability will be tested through repeated evaluations by different operators. The primary outcome is the development of the ultrasound prediction model on the day of FEES. Secondary outcomes include assessing the accuracy and reliability of tongue, hyoid, and muscle characteristics. The study includes ongoing monitoring and data recording during the enrollment period.

Age: 18Years +All Genders
4 locations
S

Actively Recruiting

Tapia syndrome is a rare condition characterized by paralysis of a vocal cord and the same side of the tongue, caused by damage to the recurrent and hypoglossal nerves. This condition leads to difficulties with voice and swallowing. The syndrome is mostly unilateral but can be bilateral, and its exact prevalence and clinical features are not well understood, with fewer than 100 cases reported in medical literature to date. This observational study aims to determine how common Tapia syndrome is among patients admitted to a weaning unit after prolonged orotracheal intubation lasting more than 48 hours. It also seeks to describe the clinical signs such as tongue and soft palate involvement, voice and swallowing impairments, and to identify factors linked with the syndrome. Diagnosis involves clinical tongue examination, nasofibroscopy, and ultrasound. Participants are hospitalized patients in the weaning unit who have undergone long-term intubation and meet specific health criteria. Researchers will assess their neurological and ENT status, perform swallowing tests, and use imaging methods shortly after inclusion. Outcomes measured include the prevalence of Tapia syndrome over about two years, swallowing and voice function, and associated clinical features. The study collects data throughout the participants stay and follow-up period to better understand the condition.

Age: 18Years +All Genders
1 location
N

Actively Recruiting

Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.

Age: 18Years +All GendersPhase Not Applicable
83 locations